We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+2.9%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.56B
AUM Growth
-$71.2M
(-2.7%)
Cap. Flow
-$99.6M
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
27
Reduced
32
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$20M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$14.2M |
| 3 |
Amgen
AMGN
|
+$14.1M |
| 4 |
Insulet
PODD
|
+$13.3M |
| 5 |
Baxter International
BAX
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$31.7M |
| 2 |
Cigna
CI
|
+$22.5M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$22.3M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$13.8M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$13.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.28% |
| 2 | Real Estate | 2.09% |
| 3 | Miscellaneous | 1.37% |
| 4 | Industrials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DOC
51
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $12.2M | 0.48% |
873,655
| – | – |
|
52
Tenet Healthcare
THC
$21B
| $12.1M | 0.47% |
+149,070
| New | +$10.6M |
|
53
BioNTech
BNTX
$24.3B
| $11.2M | 0.44% |
103,858
| – | – |
|
54
Neurocrine Biosciences
NBIX
$15.2B
| $10.6M | 0.42% |
112,908
| – | – |
|
55
Zimmer Biomet
ZBH
$18.8B
| $9.81M | 0.38% |
67,356
| – | – |
|
56
Rallybio
RLYB
$91.4M
| $9.78M | 0.38% |
215,883
| – | – |
|
57
Vaxcyte
PCVX
$8.81B
| $9.7M | 0.38% |
194,232
+189,232
| +3,785% | +$8.97M |
|
58
Alkermes
ALKS
$7.72B
| $9.69M | 0.38% |
309,613
| – | – |
|
59
Denali Therapeutics
DNLI
$3.26B
| $9.59M | 0.38% |
324,829
| – | – |
|
60
Avantor
AVTR
$10.4B
| $9.44M | 0.37% |
459,488
| – | – |
|
61
Omega Healthcare
OHI
$14.3B
| $9.4M | 0.37% |
306,433
| – | – |
|
62
United Therapeutics
UTHR
$21.5B
| $9.15M | 0.36% |
41,465
-19,735
| -32% | -$4.37M |
|
|
ITCI
63
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $8.32M | 0.33% |
131,435
-40,936
| -24% | -$2.55M |
|
64
Acadia Healthcare
ACHC
$2.55B
| $8.04M | 0.31% |
100,912
-85,575
| -46% | -$6.18M |
|
65
Madrigal Pharmaceuticals
MDGL
$12.1B
| $7.95M | 0.31% |
34,434
+21,953
| +176% | +$5.95M |
|
66
ResMed
RMD
$33.1B
| $7.58M | 0.3% |
34,704
-38,485
| -53% | -$8.58M |
|
|
HZNP
67
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $7.45M | 0.29% |
+72,425
| New | +$7.64M |
|
68
Inspire Medical Systems
INSP
$2.16B
| $7.15M | 0.28% |
+22,018
| New | +$6.29M |
|
69
Cytokinetics
CYTK
$9.64B
| $7.14M | 0.28% |
219,025
| – | – |
|
70
Steris
STE
$20.5B
| $6.99M | 0.27% |
31,072
| – | – |
|
71
Sanofi
SNY
$102B
| $6.65M | 0.26% |
123,454
| – | – |
|
|
RCM
72
DELISTED
R1 RCM Inc. Common Stock
RCM
| $6.58M | 0.26% |
356,851
| – | – |
|
73
CVS Health
CVS
$121B
| $6.47M | 0.25% |
93,621
| – | – |
|
74
Medpace
MEDP
$17.3B
| $6.46M | 0.25% |
26,918
+17,483
| +185% | +$3.63M |
|
75
Immunovant
IMVT
$7.57B
| $6.38M | 0.25% |
336,200
+220,800
| +191% | +$4.12M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Tekla Capital Management held 186 positions worth $2.56B, down 2.7% from $2.63B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Tekla Capital Management withdrew a net $99.6M in Q2 2023, closing 20 positions and reducing 32 holdings. Its most notable exit was Travere Therapeutics, an estimated $9.41M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Miscellaneous.
Against the trend, Tekla Capital Management opened a new position in Insulet worth $12.6M.
- Tekla Capital Management's largest Q2 2023 buy was Insulet: 43,847 shares worth $12.6M.
- Tekla Capital Management added most to Merck in Q2 2023, an estimated $20M increase.
- Tekla Capital Management's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $31.7M.
- Tekla Capital Management fully exited Travere Therapeutics in Q2 2023, selling an estimated $9.41M.
- Tekla Capital Management's ten largest holdings make up 40% of its $2.56B portfolio in Q2 2023.
- Tekla Capital Management opened 9 new positions and closed 20 in Q2 2023.
- Tekla Capital Management's portfolio value fell 2.7% quarter-over-quarter to $2.56B.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.